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Microglia play a key role in defending central nervous system from various internal and external threats. However, their excessive
and/or chronic activation is associated with deleterious effects in a variety of neurodegenerative diseases. Previously, we have
shown that ribavirin when applied in clinically relevant dosage (10 𝜇M)modulates activatedmicroglia in complex fashion inducing
both anti- and proinflammatory effects, simultaneously causing cytotoxicity. Here, we examined potential of low-dose ribavirin
(0.1 and 1 𝜇M) to modulate activated BV-2 microglia. Morphological and functional activation of BV-2 cells was achieved with
lipopolysaccharide (LPS) stimulation. Our results demonstrated that low-dose ribavirin did not induce cell death, while 10 𝜇M
ribavirin promoted LPS induced apoptosis. We determined that 1 𝜇M ribavirin was equally efficient in deactivation of LPS induced
morphological changes as 10𝜇Mribavirin treatment. Ribavirin showed halfway success in reducingmarkers of functional activation
of microglia. Namely, none of the doses had effect on LPS triggered production of proinflammatory cytokine tumor necrosis factor
alpha. On the other hand, low-dose ribavirin proved its effectiveness in reduction of another inflammatorymediator, nitric oxide, by
inhibiting inducible form of nitric oxide synthase. Our results imply that low-dose ribavirin may alleviate nitrosative stress during
neuroinflammation.
1. Introduction
Microglia are resident cells of the central nervous system
(CNS) with immune function. Once they sense pathogen-
or danger-associated molecular patterns, microglia cells
go through morphological and functional activation [1].
Activated microglia migrate to the endangered area, exert
phagocytic activity to remove external antigen and potential
deleterious debris, and begin to secrete number of proin-
flammatory factors, such as tumor necrosis factor-alpha
(TNF-𝛼), nitric oxide (NO), reactive oxygen species, and
prostaglandin E2 [2]. In this way tissue repair is promoted,
so it is generally accepted that activation of microglia is
beneficial [3–5]. On the other hand, excessive microgliosis
or sustained chronic activation of microglia underlies many
neurological disorders, including multiple sclerosis [6].
Ribavirin (RBV, 1-𝛽-D-ribofuranosyl-1,2,4-triazole-3-
carboxamide, also known as Virazole) is a synthetic guano-
sine analogue exerting strong antiviral activity against variety
of RNA andDNA viruses [7]. Biochemical and pharmacolog-
ical data revealed that primary molecular target of ribavirin
action is inosine monophosphate dehydrogenase (IMPDH),
a key enzyme in de novo synthesis of guanine nucleotides [8].
Inhibition of IMPDH by RBV results in cellular depletion
of GTP. Apart from viruses, different cell types of immune
system, including subtypes of T cells [9–12], macrophages
[13], and dendritic cells [14], are sensitive to RBV action.
Immunomodulatory and immunosuppressive actions of RBV
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have been additionally evidenced in experimental autoim-
mune encephalomyelitis (EAE), an in vivo animal model of
multiple sclerosis. RBV strongly affects immune branch of
EAE as evidenced by decreased number of mononuclear cell
infiltrates [15] and suppressed production of proinflamma-
tory cytokines IFN-𝛾, IL-1𝛽, and TNF-𝛼 in draining lymph
nodes [16]. As result of prevented infiltration of the immune
cells in the CNS during EAE, RBV modulated glial cell
response, indicated by smaller number of reactive astrocytes
[17] and activated microglial cells [15]. It is of note that RBV
readily crosses blood-brain barrier [18, 19], especially the
one compromised by neuroinflammation [20]. Therefore,
RBV might directly act on glial cells within CNS. Indeed, we
have shown that RBV has capability to modulate activated
microglia in vitro [21]. However, dosage of ribavirin (10 𝜇M)
applied on activated primary microglia, although therapeuti-
cally recommended [22], induced anti- and proinflammatory
properties with simultaneous moderate cytotoxicity [21].
Therefore, in the present study we used BV-2 microglial
cell line activated with bacterial wall lipopolysaccharide
(LPS) to explore the potency of RBV when applied in low-
doses, which are ten to hundred times lower than clinically
relevant ones. In such experimental design, we have evaluated
the ability of RBV to induce apoptosis, alterations in cell mor-
phology, release of TNF-𝛼, NO production, and induction of
inducible nitric oxide synthase (iNOS), which constitute the
hallmarks of activated microglia in vivo.
2. Material and Methods
2.1. Cell Culture. BV-2 microglial cell line was a generous gift
from Dr. Alba Minelli (University of Perugia, Perugia, Italy).
Cells were cultured in RPMI 1640 medium supplemented
with 10% heat inactivated fetal calf serum (FCS) and 1%
penicillin/streptomycin, all purchased from PAA Labora-
tories GmbH, Pasching, Austria. When cultures reached
confluence, they underwent passages by trypsinization and
were seeded in different plates depending on the experiment.
The cells were pretreated with RBV (0.1, 1, and 10 𝜇M) for
30 minutes prior to stimulation with LPS (100 ng/mL) from
Escherichia coli serotype 026:B6 (Sigma-Aldrich Chemie
GmbH,Munich,Germany) for additional 24 h.The treatment
protocol was applied in all experiments of this study. RBVwas
a kind gift fromMP Biomedicals, LLC (Illkirch, France).
2.2. Flow Cytometry. BV-2 cells (2.5 × 105/well) were seeded
in 6-well plates, treated with ribavirin and LPS as described
above. Assessment of cell viability involved double staining of
cells with Annexin V-FITC (Santa Cruz, Dallas, Texas, USA)
and propidium iodide (PI; BD Pharmingen, San Diego, CA,
USA). Annexin V binds to phosphatidylserine, exposed on
the surface of early apoptotic cells, while PI uptake is marker
for necrotic or later apoptotic cell death. Negative staining for
both dyes was characteristic of viable cells. Staining was per-
formed according to the manufacturer’s instructions. Flow
cytometry was conducted on CyFlow Space Partec (Partec
GmbH, Munster, Germany) and the data was analyzed using
PartecFloMax software (Partec GmbH, Munster, Germany).
2.3.Morphological Analysis. Morphological analysis was per-
formed using phalloidin fluorescence microscopy. Cells were
plated at 8 × 104 on glass coverslips (Ø25mm) in 35mm
dishes (Sarstedt, Newton, NC, USA). After the treatment,
cells were fixed with 4% paraformaldehyde for 20min at 4∘C,
washed with PBS, and then permeabilized with Triton X-
100 (0.25%, Sigma-Aldrich, Munich, Germany) for 15min.
After blockade in 5% bovine serum albumin (BSA, Sigma-
Aldrich, Munich, Germany) actin filaments were stained by
incubating cells (30min, RT) with Alexa Fluor 555 phalloidin
(Invitrogen, Carlsbad, CA, USA) at 1 : 50 in PBS. Cells
were washed with PBS and counterstained with Hoechst
33342 (5 𝜇g/mL, Life Technologies, Invitrogen, Carlsbad, CA,
USA). Cells were coverslipped with Mowiol (Calbiochem,
Darmstadt, Germany) and images were acquired using Zeiss
Axiovert fluorescent microscope (Zeiss, Jena, Germany). To
quantitatively characterize cell morphology we used AxioVi-
sion Rel. 4.6 software, which automatically measures the 2D
cell surface area. Cells were analyzed in five randomareas (138
× 104 𝜇m2) per coverslip, with three coverslips for each group,
in three independent cell preparations.
2.4. NO Production. Concentrations of NO in the cul-
ture supernatant were determined by measuring nitrite,
a major stable product of NO, using the Griess reagent.
Cells (5 × 104/well) were cultured in 24-well plates and
treated as described. Aliquot of 100 𝜇L of each culture
medium was mixed with an equal volume of Griess reagent
(1% sulfanilamide (Sigma, Munich, Germany)/0.1% N-(1-
naphthyl)-ethylenediamine dihydrochloride (Fluka, Buchs,
Switzerland)/2.5% H
3
PO
4
). Spectrophotometric measure-
ments were performed using the LKB 5060-006 ELISA plate
reader, at 540/670 nm test/reference wavelengths. Nitrite
concentrations were calculated from the standard curve
generated using known concentrations of sodium nitrite
(NaNO
2
; Merck, Darmstadt, Germany).
2.5. Western Blot Analysis and Immunofluorescence. BV-2
cells were plated in 6-well plates at a density of 2.5 × 105
cells/well, treated for 24 hours, harvested by trypsinization,
and centrifuged at 750×g for 3min. Pelleted cells were
lysed in ice-cold lysis Triton X-100 buffer (50mM Tris-HCl,
pH 7.4, 150mM NaCl, 1% Triton X-100, and 0.1% sodium
dodecyl sulphate (SDS)) in which protease inhibitor (Roche,
Penzberg, Germany) was added. Cell lysates were centrifuged
at 17 900×g for 20min at 4∘C, and supernatants were
collected. Protein content was determined using the BCA
protein assay kit (Pierce Biotechnology, Rockford, IL, USA).
Protein samples (20𝜇g)were separated by 7.5%SDSpolyacry-
lamide gel electrophoresis with 100–120V and transferred
onto a polyvinylidene fluoride (PVDF) membrane (Roche,
Penzberg, Germany) for 1 h at 100V with cooling. The mem-
brane was blocked with 5% BSA dissolved in Tris-buffered
saline Tween-20 (TBST) (20mMTris, pH 7.6, 136mM NaCl,
and 0.1% Tween-20) for 1 h at room temperature. Membranes
were incubated with anti-iNOS antibody (1 : 500; Abcam,
Cambridge, UK) overnight at 4∘C, washed with TBST for
10min three times, and then incubated with HRP-conjugated
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secondary antibody (1 : 5000; Santa Cruz, Dallas, Texas, USA)
for 1 h at room temperature. After washing, protein bands
were visualized using chemiluminescence and developed
onto film (KODAK).The relative expression levels of proteins
were determined by densitometry using ImageQuant 5.2
software and were normalized against 𝛽-actin.The results are
expressed as the percentage of control (nontreated cells). Data
presented in graphs are mean values ± standard error of the
mean obtained from four immunoblots.
For immunofluorescence labeling, cells (8 × 104) were
plated on glass coverslips (Ø25mm) in 35mm dishes. After
24 h treatment, cells were fixed, washed, permeabilized, and
blocked with 5% BSA as described previously. Primary rabbit
anti-iNOS antibodies (1 : 700; Abcam, Cambridge, UK) were
applied overnight at 4∘C. Cells were rinsed and incubated
with fluorophore-labeled secondary antibodies (1 : 500; don-
key anti-rabbit Alexa-488, Invitrogen, Carlsbad, CA, USA)
for 1 h at room temperature. After rinsing the cells with
PBS, nuclei were counterstained with Hoechst 33342 and
coverslips were mounted with Mowiol. For the negative
control of staining, the same procedure was applied without
incubating the cells with the primary antibodies.
2.6. Enzyme-Linked Immunosorbent Assay. Enzyme-linked
immunosorbent assay (ELISA) was used to determine the
levels of TNF-𝛼 in cell-free supernatants. Cells were seeded
in 24-well plates (5 × 104/well), treated for 24 hours as
described, and culture supernatants were collected. Levels of
TNF-𝛼weremeasured using the commercial kit (eBioscience,
Frankfurt, Germany) according to the manufacturer’s proto-
col. Briefly, after incubation with biotinylated detection anti-
body, avidin-HRP conjugate and subsequently chromogenic
substrate 3,3󸀠,5,5󸀠-tetramethylbenzidine (TMB, eBioscience,
Frankfurt, Germany) were added. Color development was
ceased by adding 1M H
3
PO
4
and absorbance was mea-
sured at 450 nm. Concentrations of TNF-𝛼 in the culture
mediumwere determined using the standard curve generated
using known concentrations of recombinant murine TNF-𝛼.
Release values were calculated as pg cytokine per mL.
2.7. Statistical Analyses. Data values represent the mean ±
SEM. Statistical significance was determined using analysis
of variance that was followed by Bonferroni’s test. A value of
𝑃 < 0.05 was considered as statistically significant.
3. Results
3.1. Cell Viability Assay. The effect of low-dose RBV treat-
ment on viability of BV-2 cells (Figure 1(a)) in the culture
was evaluated after 24 h, by Annexin V/Propidium iodide
staining, which differentiates between live (AnnexinV−/PI−),
early apoptotic (Annexin V+/PI−), late apoptotic (Annexin
V+/PI+), and necrotic cells (Annexin V−/PI+). LPS decreased
the number of viable cells in culture by increasing the
number of early apoptotic cells (Figures 1(b) and 1(f)). RBV
administrated at the highest concentration (10 𝜇M) added to
the effect of LPS, by promoting the apoptosis (Figures 1(e)
and 1(f)). In contrast, lower RBV doses (0.1 and 1𝜇M) did not
affect viability of BV-2 cells (Figures 1(c), 1(d), and 1(f)). The
percentage of late apoptotic and necrotic cells did not vary
significantly among the treatments (Figure 1(f)).
3.2. Ribavirin Reorganizes Cytoskeleton of Activated BV-2
Cells. BV-2 cells (Figure 2(a)) stimulated with LPS developed
typical morphology of activated microglia, reflected in an
increase in the cell surface area and formation of multiple
membrane protrusions (Figures 2(b) and 2(f)). After the RBV
treatment (1 𝜇Mand 10 𝜇M) cells reverted to the morphology
they had before LPS stimulation (Figure 2(a)), developing
round cell body with decreased cell surface area (Figures
2(d)–2(f)). Ribavirin at the lowest dose (0.1 𝜇M) failed to
induce morphological changes in activated BV-2 cells (Fig-
ures 2(c) and 2(f)).
3.3. Ribavirin Does Not Affect Production of TNF-𝛼 in Acti-
vated BV-2 Cells. Morphological activation of microglia after
LPS stimulation was accompanied with functional activation
manifested through prominent release of proinflammatory
cytokine TNF-𝛼 (Table 1). Nevertheless, ribavirin treatment
did not affect production of this cytokine in any of the applied
dosages (Table 1).
3.4. Low-Dose RBV Treatment Reduces LPS Induced NO
Release by BV-2 Cells. Potency of low-dose RBV to sup-
press LPS induced NO release was evaluated by measuring
accumulation of nitrites in the culture medium. Surprisingly,
10 𝜇M RBV failed to induce either inhibitory or stimulatory
effect on NO production, while lower RBV doses (0.1 and
1 𝜇M) decreased NO levels to about one-half of the level
induced by LPS (Figure 3(a)). Since NO is the product of
iNOS catalytic activity, the next step was to assess expression
level of iNOS by Western blot and immunofluorescence
labeling (Figures 3(b) and 3(c)). LPS induced 3-fold increase
in the iNOS protein abundance, whereas RBV, at dosages 0.1
and 1 𝜇M, decreased expression of iNOS to a level comparable
with the untreated cells. Ribavirin at the highest dosage
(10 𝜇M) remained without effect (Figure 3(b)).
Expression of iNOS was evaluated by immunofluores-
cence labeling in LPS-activated BV-2 microglia (Figure 3(c)).
In accordance with theWestern blot analysis data, expression
of iNOS was suppressed by 0.1 and 1𝜇M RBV, while 10 𝜇M
RBV was ineffective.
4. Discussion
It is well known that the challenge of cultured microglia with
inflammatory stimuli, such as LPS, induces both activation
and apoptosis of the cells [23]. The treatment-induced cell
loss may represent a self-regulatory mechanism of microglial
activation [24] as the cell loss was found to be involved in
the resolution of inflammation [23]. Indeed, in our study
LPS induced apoptosis in about 10% of BV-2 cells in culture,
whereas 10 𝜇M RBV increased the number of apoptotic
cells for additional 10%. The same RBV dosage has been
already shown to induce comparable level of cell death in
macrophages [25] and in primary microglia [21]. Since we
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Table 1: Release of TNF-𝛼 from activated BV-2 cells treated with RBV.
Groups C LPS LPS + 0.1 𝜇M RBV LPS + 1 𝜇M RBV LPS + 10𝜇M RBV
TNF-𝛼 (pg/mL) 50 ± 23 2110 ± 95∗ 2114 ± 59 2361 ± 84 2157 ± 175
∗
𝑃 < 0.05 versus control group (C).
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Figure 1: AnnexinV/PI stainingwas analyzedwith FACS after 24 h of RBV treatment and LPS stimulation. Representative dot plots are shown
for control (a), LPS (b), and LPS stimulated BV-2 cells treated with 0.1 𝜇M (c), 1 𝜇M (d), and 10 𝜇M RBV (e). (f) Histogram representing
percentage of live, early apoptotic, and dead cells after RBV pretreatment and LPS stimulation. Data represent mean ± SEM from three
independent cell preparations. ∗𝑃 < 0.05 versus control group, #𝑃 < 0.05 versus LPS stimulated group.
found no evidence of significant apoptosis or necrosis with
low-dose RBV treatments (0.1 and 1 𝜇M), the aim of present
study was to explore if the low RBV dosages have ability to
attenuate the signs of inflammatory activation of microglia in
vitro.
The results clearly show that the low-doseRBV treatments
do not affect TNF-𝛼 production but suppress production of
NOby interferingwith the induction of inducible formofNO
synthase (iNOS). At the same time, low-dose RBV treatments
(1 𝜇M) were effective in reverting BV-2 cell morphology to
their nonactivated state, that is, the cell morphology observed
in control, nonstimulated culture. These findings suggest
that lower dosages of RBV, which do not induce cell death,
may be equally effective in reducing the signs of microglial
activation and may help explain previously published in
vivo data, showing efficiency of RBV treatment to attenuate
neuroinflammation in EAE and traumatic brain injury [16,
26].
Ribavirin efficiently reverted LPS-activated BV-2 cells
into their quiescent morphology, by inducing the actin
cytoskeleton rearrangement and decrease in mean cell body
area. Our recent study demonstrated that efficiency of 10 𝜇M
RBV to revert LPS induced alterations in cellmorphology [21]
was probably due to its ability to reduce intracellular GTP
pool beyond the level necessary for proper organization of
the cytoskeleton network [27, 28]. Present study has shown
that RBV at ten times lower dose was comparably efficient to
induce similar cytoskeleton reorganization without affecting
BV-2 cells viability.
TNF-𝛼 is one of the master cytokines produced by
activated microglia during inflammatory states in vivo [29,
30]. Results of our study have clearly demonstrated that RBV,
in full range of applied dosages, did not affect production of
the cytokine by LPS-activated BV-2 cells. Some previously
published studies reported that RBVdecreasedTNF-𝛼 release
in some cell types, includingmacrophages and dendritic cells
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Figure 2: Morphology of BV-2 cells upon 24 h of LPS stimulation and RBV treatment. Phalloidin/Hoechst fluorescent staining (red/blue)
of control (a), LPS (b), and LPS stimulated BV-2 cells treated with 0.1 (c), 1 (d), and 10𝜇M RBV (e). (f) Cell surface area was measured
using AxioVision Rel. 4.6 software, in five areas (138 × 104𝜇m2) per each coverslip (𝑛 = 3) per experimental group in three independent
experiments. Bars represent mean surface areas (±SEM) obtained from data presented in (a)–(e). ∗𝑃 < 0.05 versus control group, #𝑃 < 0.05
versus LPS stimulated group. Scale bar (a)–(e): 50 𝜇m.
[13, 14]. Therefore, results of previous and the present study
suggest that modulatory effect of RBV on TNF-𝛼 release is
cell type specific and depends on the stimuli [13] and RBV
dosage [31].
Nitric oxide is important regulatorymolecule in the CNS,
in both physiological and pathological conditions. It may
exert both neuroprotective and neurotoxic effects depending
on its overall concentration [32]. In general, overproduction
of NO by activated microglial cell is one of the hallmarks of
neuroinflammation [33, 34] and the response is associated
with the progression of several neurodegenerative diseases
[32, 35]. After the inflammatory challenge, level of NO
increases severalfold and for a prolonged period of time,
due to the induction of inducible form of NOS, which may
lead to nitrosative stress and cell death. Therefore, agents
with the ability to interfere with iNOS expression may be
beneficial in the treatment of conditions associated with the
overproduction of NO, including septic shock, inflammation,
and neurodegenerative diseases [32, 36]. In our in vitro
model, low-dose RBV treatment reduced iNOS expression
and production of NO, as it was previously reported [37–
39]. The effect of RBV was probably due to the inhibition
of the catalytic action of IMPDH, which induces a reduction
of the intracellular pool of guanosine-based nucleotides and
consequently decreases level of tetrahydrobiopterin, which
is cofactor required for the iNOS activity [38, 40]. It has
been recently shown that RBV reduces rate of nucleocyto-
plasmic transport of iNOS mRNA in IMPDH independent
pathway [41], indicating that RBV modulates iNOS expres-
sion through multiple ways. Nevertheless, the effect of RBV
seems to be dose dependent, as RBV at dose of 10𝜇M
failed to produce any effect on iNOS expression and NO
release.
Here we employed pretreatment with RBV and showed
its potential preventative ability. However, previously we
demonstrated that RBV is efficient in terminating neuroin-
flammation in vivo [42, 43] and our earlier in vitro research
also showed the potential of this drug to modulate activated
microglia even when applied simultaneously with LPS [21].
Altogether, RBV is a drug with potential preventative and
therapeutic property in neuroinflammation.
5. Conclusion
Given the fact that overproduction of NO by activated
microglia during the neuroinflammation leads to the devel-
opment of reactive nitrogen species, such as peroxynitrite,
nitrogen dioxide, which exert devastating effects on the
neuronal cells (reviewed in [32]), obtained results strongly
suggest that low-dose RBV treatment may be neuropro-
tective, due to low toxicity and high efficiency in NO
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Figure 3: (a) Effect of RBV on LPS triggered production ofNO. (b) RepresentativeWestern blot of iNOS expression. Graph showsmean iNOS
protein abundance (± SEM), from 𝑛 = 3 separate determinations, expressed relative to the abundance of 𝛽-actin in each lane. Significance
inside the graphs (a) and (b): ∗𝑃 < 0.05 versus control group, #𝑃 < 0.05 versus LPS stimulated group. (c) Panel of immunofluorescence
labeling of BV-2 cells against iNOS (green) and counterstained with Hoechst (blue) after 24 h of stimulation with LPS and treatment with
RBV. Scale bar for all pictures in panel (c): 50𝜇m.
suppression. Attenuation of nitrosative stress through the
modulation of iNOS could be beneficial if applied early
in neuroinflammatory states associated with demyelinating
diseases [44, 45], such as multiple sclerosis.
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